Breaking News, Financial News

Financial Report: Mylan

EpiPen drives Specialty segment sales up 38%

Mylan

4Q Revenues: $2.1 billion (+18%)

4Q Earnings: $190.5 million (+5%)

FY Revenues: $7.7 billion (+13%)

FY Earnings: $933.1 million (+49%)

Comments: Generics segment sales were $1.8 billion in the quarter, up 16%, with North American sales of $1.0 billion, up 17%; European sales of $373.4 million, down 1%; and Rest of World sales were $441.0 million, up 13%. Specialty segment sales were $242.7 million, up 38% driven by EpiPen Auto-Injector sales with increased volume and favorable pricing.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters